BDTX — BLACK DIAMOND THERAPEUTICS I

Public company

Sign in to save1 tracked investor reported this
For educational research only.InvestorLens analyzes public regulatory filings (SEC EDGAR, STOCK Act PTRs) that may be delayed by 45 days or more. Information shown is historical and is not financial, legal, or tax advice, nor a recommendation or solicitation to buy or sell any security. Always do your own research.

InvestorLens aggregates public filing data to show which tracked investors reported holdings in this stock. Dollar values represent reported position values, not market capitalization, and may be delayed up to 45 days. Not a recommendation.

Sourced from SEC EDGAR public filings

About BLACK DIAMOND THERAPEUTICS I (BDTX)

BLACK DIAMOND THERAPEUTICS I (BDTX) appears in the most recent 13F filings of 1 tracked institutional investor. The largest disclosed position is held by Ken Griffin (Citadel Advisors), valued at $1M. All data sourced from SEC 13F filings.

Tracked investors reporting BDTX

  • Ken GriffinDec 31, 2025
    Citadel Advisors
    Shares
    488.8K
    Value
    $1.2M
    % Portfolio
    0.00%

Recent activity

  • No recent activity.

Frequently asked questions

How many institutional investors hold BDTX?
1 tracked institutional investor disclosed a position in BDTX (BLACK DIAMOND THERAPEUTICS I) in their most recent 13F filing.
Who is the largest institutional holder of BDTX?
Ken Griffin, Citadel Advisors, holds the largest disclosed position in BDTX, valued at $1M.
Did institutional ownership of BDTX increase or decrease?
Across recent 13F filings, tracked investors recorded 0 new positions, 0 increased, 0 reduced, and 0 fully exited BDTX.
Where does this BDTX ownership data come from?
SEC Form 13F-HR filings, accessed via EDGAR. 13F filings are disclosed quarterly with a 45-day reporting delay and cover U.S.-listed long equity positions only. This is not investment advice.